Trial Profile
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Losatuxizumab-vedotin (Primary)
- Indications Advanced breast cancer; Carcinoma; Colon cancer; Colorectal cancer; Glioblastoma; Head and neck cancer; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 17 Sep 2021 Results from NCT02099058, NCT02365662, NCT02462525 and NCT02565758 assessing Neutropenia, presented at the 2021 American College of Clinical Pharmacology Annual Meeting
- 18 Mar 2020 Results assessing describes the safety, pharmacokinetic (PK) profile, and preliminary efficacy results of losatuxizumab vedotin in patients with solid tumors likely to overexpress EGFR and/or EGFR ligands published in the Investigational New Drugs
- 23 Mar 2018 Status changed from active, no longer recruiting to discontinued.